Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Rationale and objectives: Novel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds. Methods: Five of these compounds (BB-22, FUB-PB-22, 5F-AMB, NM2201, and MAB-CHMINACA) were tested for their ability to produce discriminative stimulus effects similar to Δ9-tetrahydrocannabinol (Δ9-THC) in rats. The ability of the CB1 receptor inverse agonist rimonabant to antagonize the discriminative stimulus effects of the five test compounds was also tested. Results: All five of the test compounds fully substituted for the discriminative stimulus effects of Δ9-THC at some dose, although MAB-CHMINACA produced an inverted U-shaped dose effect. Rimonabant fully antagonized the Δ9-THC-like discriminative stimulus effects of BB-22, 5F-AMB, NM2201, and MAB-CHMINACA but only reduced the effects of FUB-PB-22 to 40–50 % of Δ9-THC-appropriate responding. Conclusions: These findings suggest that all five of the test compounds produced Δ9-THC-like effects and will likely have abuse liability similar to that of the controlled cannabinoid compounds.

Original languageEnglish
Pages (from-to)673-680
Number of pages8
JournalPsychopharmacology
Volume235
Issue number3
DOIs
StatePublished - 1 Mar 2018

Fingerprint

Dronabinol
Cannabinoids
rimonabant
Cannabinoid Receptor CB1
Controlled Substances
Cannabis

Keywords

  • Abuse liability
  • Cannabinoids
  • Drug discrimination
  • Locomotor activity
  • Mouse
  • Rat

Cite this

@article{d3257b1993544cb0b97a0b7dad263512,
title = "Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats",
abstract = "Rationale and objectives: Novel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds. Methods: Five of these compounds (BB-22, FUB-PB-22, 5F-AMB, NM2201, and MAB-CHMINACA) were tested for their ability to produce discriminative stimulus effects similar to Δ9-tetrahydrocannabinol (Δ9-THC) in rats. The ability of the CB1 receptor inverse agonist rimonabant to antagonize the discriminative stimulus effects of the five test compounds was also tested. Results: All five of the test compounds fully substituted for the discriminative stimulus effects of Δ9-THC at some dose, although MAB-CHMINACA produced an inverted U-shaped dose effect. Rimonabant fully antagonized the Δ9-THC-like discriminative stimulus effects of BB-22, 5F-AMB, NM2201, and MAB-CHMINACA but only reduced the effects of FUB-PB-22 to 40–50 {\%} of Δ9-THC-appropriate responding. Conclusions: These findings suggest that all five of the test compounds produced Δ9-THC-like effects and will likely have abuse liability similar to that of the controlled cannabinoid compounds.",
keywords = "Abuse liability, Cannabinoids, Drug discrimination, Locomotor activity, Mouse, Rat",
author = "Gatch, {Michael B.} and Forster, {Michael J.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s00213-017-4783-6",
language = "English",
volume = "235",
pages = "673--680",
journal = "Psychopharmacologia",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. / Gatch, Michael B.; Forster, Michael J.

In: Psychopharmacology, Vol. 235, No. 3, 01.03.2018, p. 673-680.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats

AU - Gatch, Michael B.

AU - Forster, Michael J.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Rationale and objectives: Novel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds. Methods: Five of these compounds (BB-22, FUB-PB-22, 5F-AMB, NM2201, and MAB-CHMINACA) were tested for their ability to produce discriminative stimulus effects similar to Δ9-tetrahydrocannabinol (Δ9-THC) in rats. The ability of the CB1 receptor inverse agonist rimonabant to antagonize the discriminative stimulus effects of the five test compounds was also tested. Results: All five of the test compounds fully substituted for the discriminative stimulus effects of Δ9-THC at some dose, although MAB-CHMINACA produced an inverted U-shaped dose effect. Rimonabant fully antagonized the Δ9-THC-like discriminative stimulus effects of BB-22, 5F-AMB, NM2201, and MAB-CHMINACA but only reduced the effects of FUB-PB-22 to 40–50 % of Δ9-THC-appropriate responding. Conclusions: These findings suggest that all five of the test compounds produced Δ9-THC-like effects and will likely have abuse liability similar to that of the controlled cannabinoid compounds.

AB - Rationale and objectives: Novel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds. Methods: Five of these compounds (BB-22, FUB-PB-22, 5F-AMB, NM2201, and MAB-CHMINACA) were tested for their ability to produce discriminative stimulus effects similar to Δ9-tetrahydrocannabinol (Δ9-THC) in rats. The ability of the CB1 receptor inverse agonist rimonabant to antagonize the discriminative stimulus effects of the five test compounds was also tested. Results: All five of the test compounds fully substituted for the discriminative stimulus effects of Δ9-THC at some dose, although MAB-CHMINACA produced an inverted U-shaped dose effect. Rimonabant fully antagonized the Δ9-THC-like discriminative stimulus effects of BB-22, 5F-AMB, NM2201, and MAB-CHMINACA but only reduced the effects of FUB-PB-22 to 40–50 % of Δ9-THC-appropriate responding. Conclusions: These findings suggest that all five of the test compounds produced Δ9-THC-like effects and will likely have abuse liability similar to that of the controlled cannabinoid compounds.

KW - Abuse liability

KW - Cannabinoids

KW - Drug discrimination

KW - Locomotor activity

KW - Mouse

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=85033708350&partnerID=8YFLogxK

U2 - 10.1007/s00213-017-4783-6

DO - 10.1007/s00213-017-4783-6

M3 - Article

VL - 235

SP - 673

EP - 680

JO - Psychopharmacologia

JF - Psychopharmacologia

SN - 0033-3158

IS - 3

ER -